Potential inhibition of CXCL12/SDF-1 by small molecule Hesperetin in management of tobacco associated oral cancer
Goal of the perspective: Stromal cell-derived factor-1 alpha CXCL12/SDF-1 has a substantial impact on the tumorigenicity in tobacco related oral cancer. Inhibition could help derive preventive and therapeutic approaches. Discussion: Binding energy score between CXCL12/SDF-1 and small molecule Hesper...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024001080 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553745564925952 |
|---|---|
| author | G. Radha Ramya Ramadoss Pradeep Kumar Yadalam Rajeshkumar Shanmugam |
| author_facet | G. Radha Ramya Ramadoss Pradeep Kumar Yadalam Rajeshkumar Shanmugam |
| author_sort | G. Radha |
| collection | DOAJ |
| description | Goal of the perspective: Stromal cell-derived factor-1 alpha CXCL12/SDF-1 has a substantial impact on the tumorigenicity in tobacco related oral cancer. Inhibition could help derive preventive and therapeutic approaches. Discussion: Binding energy score between CXCL12/SDF-1 and small molecule Hesperetin is indicative of a strong and stable interaction, significative of a high affinity for the chemokine. The specific molecular interactions, including hydrogen bonding and van der Waals interactions further contribute to the stable complex formation. Conclusion: Targeting molecular components of the NF-κB signaling pathway through inhibition of CXCL12/SDF-1 could serve as a vital therapeutic adjunct in management of tobacco associated oral cancer. Also topical drug delivery systems with Hesperetin can be planned in oral potentially malignant disorders. |
| format | Article |
| id | doaj-art-6b1c71123f6d4b6ca5b4fa6745dadca0 |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-6b1c71123f6d4b6ca5b4fa6745dadca02025-01-09T06:15:33ZengElsevierOral Oncology Reports2772-90602024-03-019100262Potential inhibition of CXCL12/SDF-1 by small molecule Hesperetin in management of tobacco associated oral cancerG. Radha0Ramya Ramadoss1Pradeep Kumar Yadalam2Rajeshkumar Shanmugam3Department of Oral Biology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, 600 077, IndiaDepartment of Oral Biology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, 600 077, India; Corresponding author.Department of Periodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, 600 077, IndiaCenter for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IndiaGoal of the perspective: Stromal cell-derived factor-1 alpha CXCL12/SDF-1 has a substantial impact on the tumorigenicity in tobacco related oral cancer. Inhibition could help derive preventive and therapeutic approaches. Discussion: Binding energy score between CXCL12/SDF-1 and small molecule Hesperetin is indicative of a strong and stable interaction, significative of a high affinity for the chemokine. The specific molecular interactions, including hydrogen bonding and van der Waals interactions further contribute to the stable complex formation. Conclusion: Targeting molecular components of the NF-κB signaling pathway through inhibition of CXCL12/SDF-1 could serve as a vital therapeutic adjunct in management of tobacco associated oral cancer. Also topical drug delivery systems with Hesperetin can be planned in oral potentially malignant disorders.http://www.sciencedirect.com/science/article/pii/S2772906024001080TobaccoHesperitinOSCCCXCL12/SDF-1ROS |
| spellingShingle | G. Radha Ramya Ramadoss Pradeep Kumar Yadalam Rajeshkumar Shanmugam Potential inhibition of CXCL12/SDF-1 by small molecule Hesperetin in management of tobacco associated oral cancer Oral Oncology Reports Tobacco Hesperitin OSCC CXCL12/SDF-1 ROS |
| title | Potential inhibition of CXCL12/SDF-1 by small molecule Hesperetin in management of tobacco associated oral cancer |
| title_full | Potential inhibition of CXCL12/SDF-1 by small molecule Hesperetin in management of tobacco associated oral cancer |
| title_fullStr | Potential inhibition of CXCL12/SDF-1 by small molecule Hesperetin in management of tobacco associated oral cancer |
| title_full_unstemmed | Potential inhibition of CXCL12/SDF-1 by small molecule Hesperetin in management of tobacco associated oral cancer |
| title_short | Potential inhibition of CXCL12/SDF-1 by small molecule Hesperetin in management of tobacco associated oral cancer |
| title_sort | potential inhibition of cxcl12 sdf 1 by small molecule hesperetin in management of tobacco associated oral cancer |
| topic | Tobacco Hesperitin OSCC CXCL12/SDF-1 ROS |
| url | http://www.sciencedirect.com/science/article/pii/S2772906024001080 |
| work_keys_str_mv | AT gradha potentialinhibitionofcxcl12sdf1bysmallmoleculehesperetininmanagementoftobaccoassociatedoralcancer AT ramyaramadoss potentialinhibitionofcxcl12sdf1bysmallmoleculehesperetininmanagementoftobaccoassociatedoralcancer AT pradeepkumaryadalam potentialinhibitionofcxcl12sdf1bysmallmoleculehesperetininmanagementoftobaccoassociatedoralcancer AT rajeshkumarshanmugam potentialinhibitionofcxcl12sdf1bysmallmoleculehesperetininmanagementoftobaccoassociatedoralcancer |